Other potent senolytics include navitoclax (ABT-263), which targets BCL-2/BCL-xL anti-apoptotic signaling, but it has shown dose-limiting thrombocytopenia in preclinical and early clinical trials (72–75). Here, BCL2 is linked to Thrombocytopenia.